Literature DB >> 29648886

BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer.

David Planchard, Bruce E Johnson1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29648886     DOI： 10.5858/arpa.2018-0088-ED

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN： 0003-9985            Impact factor:   5.534


× No keyword cloud information.
  3 in total

1.  Updated guidelines for predictive biomarker testing in advanced non-small-cell lung cancer: a National Consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology.

Authors:  P Garrido; E Conde; J de Castro; J J Gómez-Román; E Felip; L Pijuan; D Isla; J Sanz; L Paz-Ares; F López-Ríos
Journal:  Clin Transl Oncol       Date:  2019-10-09       Impact factor: 3.405

2.  Mutation-oriented profiling of autoinhibitory kinase conformations predicts RAF inhibitor efficacies.

Authors:  Johanna E Mayrhofer; Florian Enzler; Andreas Feichtner; Ruth Röck; Jakob Fleischmann; Andrea Raffeiner; Philipp Tschaikner; Egon Ogris; Roland G Huber; Markus Hartl; Rainer Schneider; Jakob Troppmair; Omar Torres-Quesada; Eduard Stefan
Journal:  Proc Natl Acad Sci U S A       Date:  2020-11-23       Impact factor: 11.205

Review 3.  BRAF-Mutated Non-Small Cell Lung Cancer: Current Treatment Status and Future Perspective.

Authors:  Ningning Yan; Sanxing Guo; Huixian Zhang; Ziheng Zhang; Shujing Shen; Xingya Li
Journal:  Front Oncol       Date:  2022-03-31       Impact factor: 6.244
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.